Pharmaceuticals company Sai Life Science announced Q1FY26 results Revenue from Operations was Rs 496 crore for Q1FY26 compared to Rs 280 crore in Q1FY25, an increase of 77% driven primarily by strong growth in CDMO segment. EBITDA stood at Rs 125 crore. for Q1FY26 compared to Rs 31 crore in Q1FY25. an increase of 305%. EBITDA margin expanded by 14% YoY to 25% in Q1FY26. PAT for Q1FY26 stood at Rs 60 crore. Invested Rs 134 crore in capital expenditure during Q1FY26. Krishna Kanumuri, Managing Director and CEO, Sai Life Sciences, said: “We have begun FY26 on a strong footing, delivering healthy performance across our Discovery, Development and Commercial Manufacturing businesses. This momentum reflects the growing trust and deepening engagement we share with our global pharma clients' relationships that continue to anchor us through macroeconomic uncertainty and broader industry cycles. As the nature of innovation in drug development evolves, we are proactively investing in the infrastructure and scientific depth required to support complex and emerging modalities. During the quarter, we inaugurated new Biology Labs that significantly strengthen our Integrated Discovery platform and enhance our ability to handle greater molecular complexity. We also broke ground on a new Process R&D; Block at our Hyderabad campus, which will nearly double our process R&D; capacity and bring in next generation, data-rich process capabilities to handle increasingly complex molecules. These are deliberate steps in our journey to be the partner of choice for advancing innovation in complex science. We remain committed to enabling our clients’ aspirations with speed, scientific rigor, and an unrelenting focus on quality." Siva Chittor, Director and Chief Financial Officer, Sai Life Sciences, said:” We are pleased to report a robust performance for Q1FY26, marked by strong growth across our Discovery and CDMO businesses. Total revenue for the quarter stood at Rs 496 crore, up 77% YoY, led by 113% growth in our CDMO segment and a 38% rise in Discovery revenues, enabled by deeper engagement with global clients. We recorded EBITDA of Rs 125 crore, growing 305% YoY, with margins expanding to 25%, an improvement of 14% YoY driven by operating leverage, scale efficiencies, and improved productivity across our sites. During the quarter, we invested Rs 134 crore in capex. This includes investments in new R&D; infrastructure and process development capabilities, enabling us to support complex and emerging modalities such as peptides, ADCs, and oligonucleotides. As we look ahead, we remain optimistic about our growth trajectory. With a strong foundation in place, we are focused on scaling execution, strengthening client partnerships, and investing in technology and talent to deliver sustained performance and long-term value.” Result PDF